Acceleration and Augmentation of Antidepressants With Lithium for Depressive Disorders: Two Meta-Analyses of Randomized, Placebo-Controlled Trials
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The delayed onset of therapeutic response and the high number of nonresponders to antidepressants remain major clinical problems in depressive disorders. Among the strategies to overcome both dilemmas, the additional treatment with lithium has been suggested as a viable method. The authors determined in 2 separate meta-analyses the efficacy of lithium in accelerating and in augmenting clinical response in patients with depression. STUDY SELECTION AND DATA SOURCES: Two meta-analyses of randomized, double-blind, placebo-controlled trials including subjects with unipolar or bipolar disorder, depressive phase, assessed the concomitant administration of lithium and antidepressant to accelerate or augment clinical response in the acute treatment phase of depression. Data were obtained from searching the following databases: MEDLINE (1966 to July 2006), EMBASE (1989 to July 2006), and The Cochrane Central Register of Controlled Trials (The Cochrane Library 2006, Issue 3). For the accelerating meta-analysis, subject headings including depressive disorder, bipolar disorder, antidepressive agents, and lithium and text words such as depress*, lithium, and antidepress* were used. For the augmentation meta-analysis, subject headings included depressive disorder, bipolar disorder, anti-depressive agents, lithium, drug therapy, and combination, and text words included augment*, refract*, and resistant. Outcomes investigated included response rates and depression scale rates. DATA SYNTHESIS: Five acceleration studies (231 participants) adding lithium to tricyclics and tetracyclics and 10 augmentation studies (269 participants) adding lithium to various antidepressants including selective serotonin reuptake inhibitors were incorporated. In the acceleration meta-analysis, a statistical trend in favor of lithium was found (standardized mean difference of -0.43, 95% CI = -0.93 to 0.07). In the augmentation meta-analysis, lithium was significantly more effective than placebo (odds ratio = 3.11, 95% CI = 1.80 to 5.37). CONCLUSION: There is firm evidence for lithium as an effective augmentation strategy but only modest evidence for lithium to accelerate response to antidepressants in patients with depressive disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The extant evidence supporting lithium and thyroid hormone largely refers to their combination with TCAs and MAOIs in patients with partial response to these agents.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [277]
Citations
Cites
Still being checked.
Cited by
Items 201–244 of 244
Lithium: Underappreciated and Underused?
(2007) · Psychiatric Annals · doi:10.3928/00485713-20070901-06
Was tun, wenn die antidepressive Behandlung versagt?
Schmauß, M. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0084-9
Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_1
Treatment of Depression with Lithium
Bauer, M., & Gitlin, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31214-9_7
Self-citationAssociation du lithium avec les antidépresseurs
Raffaitin, F. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-73727-5.00004-0
Stratégie thérapeutique des troubles de l'humeur
Bennabi, D., Masse, C., Haffen, É., Sechter, D., & Vandel, P. (2016)
Adjunctive Atypical Antipsychotics in Medication-Resistant Depression
Nelson, J. C. (2010) · CNS Spectrums · doi:10.1017/s1092852900027930
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., Bauer, M., & Adli, M. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-24904-4.00011-2
Self-citationLeitliniengerechte Pharmakotherapie der therapieresistenten Depression
Busche, M., & Bschor, T. (2017) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-017-1497-x
Mood Stabilizers: Classification, Indications and Differential Indications
Menke, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_36-1
McLaughlin, P., & Cleare, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.009
(2007) · Respirology · doi:10.1111/j.1440-1843.2007.01019.x
Lithium in Psychiatric Indications
Schefft, C., Volkmann, C., & Köhler, S. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_447-1
Writers, A. M. (2014) · Drugs & Therapy Perspectives · doi:10.1007/s40267-014-0160-2
Biomarkers of lithium efficacy in bipolar disorders
RYBAKOWSKI, J. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821398-8.00017-5
Sparks, G. M., & Axelson, D. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch11
Management of treatment nonresponse
Anderson, I. M. (2009) · doi:10.1007/978-1-907673-24-5_7
&NA; (2011) · Drugs & Therapy Perspectives · doi:10.2165/11207880-000000000-00000
Management of Treatment Nonresponse
Friedman, E. S., & Anderson, I. M. (2014) · doi:10.1007/978-1-907673-79-5_7
Ontiveros, J. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82568
Pharmakotherapie: Therapieresistenz
Regen, F. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23031-8.00017-0
Mood Stabilizers: Classification, Indications and Differential Indications
Menke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_36
Buspavanich, P., & Ricken, R. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_8
Pharmacological Approaches to Depression and Treatment-Resistant Depression
Fava, M., Baek, J. H., Nierenberg, A. A., Mischoulon, D., Cusin, C., Cassano, P., & Papakostas, G. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00051-5
Almeida, J., Spelber, D., & Smith, T. L. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as37 · Cited by 2
Pharmacological Approaches to Depression and Treatment-Resistant Depression
Fava, M., Baek, J. H., Nierenberg, A. A., Mischoulon, D., Cusin, C., Cassano, P., & Papakostas, G. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00003-x
Zweitschrittverfahren in der antidepressiven Pharmakotherapie: Ergebnisse aktueller Metaanalysen
Krabs, M., Bschor, T., Henssler, J. F., & Baethge, C. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01785-4
Tricyclic antidepressants for treatment-resistant depression
Bobo, W. V., & Richelson, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00008-6 · Cited by 4
Adjunctive strategies for treatment-resistant depression
Thase, M. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00011-6 · Cited by 1
Price, L. H. (2025) · The Brown University Psychopharmacology Update · doi:10.1002/pu.31399
(2007) · CNS Spectrums · doi:10.1017/s1092852900016047
Mehta, S. H. (2022) · TSpace (University of Toronto)
Chaikali, S., & Jacobsen, J. P. R. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002180
Eckert, D., & Kasper, S. F. (2026) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2026.2663307
Depresyon Tanıdan Tedaviye Klinik Süreç
Gül, V. (2026) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.4140
Lithium as a Potential Senostatic Agent in Central Nervous System Aging and Bipolar Disorder
RYBAKOWSKI, J. K., Mydlak, C., Klimek, N., & Książek, K. (2026) · Pharmaceuticals · doi:10.3390/ph19091378
DEPRESSÃO RESISTENTE AO TRATAMENTO: QUANDO ESCALAR A TERAPIA E REPENSAR O DIAGNÓSTICO
Bento, Y. S. G. M., Campos, N. B. F. L. B., Mota, M. F. P., Prado, M. J. A., & Neves, M. D. A. M. (2026) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v12i8.29427
Traitement médicamenteux des troubles de l’humeur
Bennabi, D., Chouk, A., Haffen, É., & Vandel, P. (2026) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(26)48448-5
Metadata
- Authors
- Crossley, N. A., & Bauer, M.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-06-15
- Volume
- 68
- Issue
- 06
- Pages
- 935-940
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2010317561
- Cited by
- 246
- References
- 0
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 11 · 2021: 5 · 2020: 13 · 2019: 11 · 2018: 12 · 2017: 12 · 2016: 9 · 2015: 9 · 2014: 19 · 2013: 20 · 2012: 16
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- lithium, antidepressant augmentation, depression, bipolar disorder, treatment-resistant depression, tricyclic antidepressants, selective serotonin reuptake inhibitors, tetracyclic antidepressants, response rate
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Drug Interactions, Drug Therapy, Combination, Humans, Randomized Controlled Trials as Topic, Lithium Carbonate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.